Abstract
Management of the stage IIIA (N2) patient remains one of the most controversial areas in thoracic oncology. The potential cur-ability of at least some of these patients has encourage the development of more complex, aggressive, and toxic multimodality treatment regimens.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 69-100 |
| Number of pages | 32 |
| Journal | Chest Surgery Clinics of North America |
| Volume | 11 |
| Issue number | 1 |
| DOIs | |
| State | Published - 2001 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
All Science Journal Classification (ASJC) codes
- Pulmonary and Respiratory Medicine
Fingerprint
Dive into the research topics of 'Evaluation and management of patients with stage IIIA (N2) non-small-cell lung cancer'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver